Market revenue in 2023 | USD 90.4 million |
Market revenue in 2030 | USD 172.7 million |
Growth rate | 9.7% (CAGR from 2023 to 2030) |
Largest segment | Pharmaceuticals |
Fastest growing segment | Devices |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Devices |
Key market players worldwide | Johnson & Johnson, Cipla Ltd DR, Sun Pharmaceutical Industries, Merck & Co Inc, Dr. Reddy’s Laboratories, Cardiff Lexington Corp, Amgen Inc, Theradome, Aurobindo Pharma, Curallux, Apira Science |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to androgenetic alopecia market will help companies and investors design strategic landscapes.
Pharmaceuticals was the largest segment with a revenue share of 98.56% in 2023. Horizon Databook has segmented the South Korea androgenetic alopecia market based on pharmaceuticals, devices covering the revenue growth of each sub-segment from 2018 to 2030.
A large population base in South Korea is suffering from alopecia, with an approximate 1.3:1 male-tofemale ratio. Market growth in the country is driven by technological advancements and new product developments. For instance, in October 2020, a South Korean company, LG Electronics, received approval for its laser therapy-based helmet for the treatment of AGA.
Local players focus on addressing unmet needs of patients. The Ministry of Food and Drug Safety (MFDS) approved the generic version of Avodart by JW Pharmaceutical, JW shinyak, Dong-A ST Co. Ltd, and Daehan New Pharm Co., Ltd. These companies are reformulating dosage forms to enhance patient compliance, as Avodart and previous generics were available in soft gelatin capsules.
Moreover, a team of scientists identified that CXXC5 protein downregulates the WNT signaling pathway, which controls hair regeneration and follicular development. In line with this, PTD-DMB is considered to be a potential biochemical agent to combat alopecia. These factors and initiatives are expected to drive market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea androgenetic alopecia market , including forecasts for subscribers. This country databook contains high-level insights into South Korea androgenetic alopecia market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account